Jeffrey J Tosoian1,2,3, Bruce J Trock4, Todd M Morgan1,2, Simpa S Salami1,2,3, Scott A Tomlins1,2,3, Daniel E Spratt2,5, Javed Siddiqui1,3, Lakshmi P Kunju3,6, Rachel Botbyl3, Zoey Chopra3, Balaji Pandian3, Nicholas W Eyrich1, Gary Longton7, Yingye Zheng7, Ganesh S Palapattu1,2, John T Wei1,8, Yashar S Niknafs3, Arul M Chinnaiyan1,2,3,6,9. 1. Department of Urology, University of Michigan, Ann Arbor, Michigan. 2. Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan. 3. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan. 4. Johns Hopkins Brady Urological Institute, Baltimore, Maryland. 5. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 6. Department of Pathology, University of Michigan, Ann Arbor, Michigan. 7. Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 8. Dow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan. 9. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan.
Abstract
PURPOSE: The MyProstateScore test was validated for improved detection of clinically significant (grade group ≥2) prostate cancer relative to prostate specific antigen based risk calculators. We sought to validate an optimal MyProstateScore threshold for clinical use in ruling out grade group ≥2 cancer in men referred for biopsy. MATERIALS AND METHODS: Biopsy naïve men provided post-digital rectal examination urine prior to biopsy. MyProstateScore was calculated using the validated, locked multivariable model including only serum prostate specific antigen, urinary prostate cancer antigen 3 and urinary TMPRSS2:ERG. The MyProstateScore threshold approximating 95% sensitivity for grade group ≥2 cancer was identified in a training cohort, and performance was measured in 2 external validation cohorts. We assessed the 1) overall biopsy referral population and 2) population meeting guideline based testing criteria (ie, prostate specific antigen 3-10, or <3 with suspicious digital rectal examination). RESULTS: Validation cohorts were prospectively enrolled from academic (977 patients, median prostate specific antigen 4.5, IQR 3.1-6.0) and community (548, median prostate specific antigen 4.9, IQR 3.7-6.8) settings. In the overall validation population (1,525 patients), 338 men (22%) had grade group ≥2 cancer on biopsy. The MyProstateScore threshold of 10 provided 97% sensitivity and 98% negative predictive value for grade group ≥2 cancer. MyProstateScore testing would have prevented 387 unnecessary biopsies (33%), while missing only 10 grade group ≥2 cancers (3.0%). In 1,242 patients meeting guideline based criteria, MyProstateScore ≤10 provided 96% sensitivity and 97% negative predictive value, and would have prevented 32% of unnecessary biopsies, missing 3.7% of grade group ≥2 cancers. CONCLUSIONS: In a large, clinically pertinent biopsy referral population, MyProstateScore ≤10 provided exceptional sensitivity and negative predictive value for ruling out grade group ≥2 cancer. This straightforward secondary testing approach would reduce the use of more costly and invasive procedures after screening with prostate specific antigen.
PURPOSE: The MyProstateScore test was validated for improved detection of clinically significant (grade group ≥2) prostate cancer relative to prostate specific antigen based risk calculators. We sought to validate an optimal MyProstateScore threshold for clinical use in ruling out grade group ≥2 cancer in men referred for biopsy. MATERIALS AND METHODS: Biopsy naïve men provided post-digital rectal examination urine prior to biopsy. MyProstateScore was calculated using the validated, locked multivariable model including only serum prostate specific antigen, urinary prostate cancer antigen 3 and urinary TMPRSS2:ERG. The MyProstateScore threshold approximating 95% sensitivity for grade group ≥2 cancer was identified in a training cohort, and performance was measured in 2 external validation cohorts. We assessed the 1) overall biopsy referral population and 2) population meeting guideline based testing criteria (ie, prostate specific antigen 3-10, or <3 with suspicious digital rectal examination). RESULTS: Validation cohorts were prospectively enrolled from academic (977 patients, median prostate specific antigen 4.5, IQR 3.1-6.0) and community (548, median prostate specific antigen 4.9, IQR 3.7-6.8) settings. In the overall validation population (1,525 patients), 338 men (22%) had grade group ≥2 cancer on biopsy. The MyProstateScore threshold of 10 provided 97% sensitivity and 98% negative predictive value for grade group ≥2 cancer. MyProstateScore testing would have prevented 387 unnecessary biopsies (33%), while missing only 10 grade group ≥2 cancers (3.0%). In 1,242 patients meeting guideline based criteria, MyProstateScore ≤10 provided 96% sensitivity and 97% negative predictive value, and would have prevented 32% of unnecessary biopsies, missing 3.7% of grade group ≥2 cancers. CONCLUSIONS: In a large, clinically pertinent biopsy referral population, MyProstateScore ≤10 provided exceptional sensitivity and negative predictive value for ruling out grade group ≥2 cancer. This straightforward secondary testing approach would reduce the use of more costly and invasive procedures after screening with prostate specific antigen.
Entities:
Keywords:
biomarkers; biopsy; early detection of cancer; prostate-specific antigen; prostatic neoplasms; tumor
Authors: Dipen J Parekh; Sanoj Punnen; Daniel D Sjoberg; Scott W Asroff; James L Bailen; James S Cochran; Raoul Concepcion; Richard D David; Kenneth B Deck; Igor Dumbadze; Michael Gambla; Michael S Grable; Ralph J Henderson; Lawrence Karsh; Evan B Krisch; Timothy D Langford; Daniel W Lin; Shawn M McGee; John J Munoz; Christopher M Pieczonka; Kimberley Rieger-Christ; Daniel R Saltzstein; John W Scott; Neal D Shore; Paul R Sieber; Todd M Waldmann; Fredrick N Wolk; Stephen M Zappala Journal: Eur Urol Date: 2014-10-27 Impact factor: 20.096
Authors: Scott A Tomlins; John R Day; Robert J Lonigro; Daniel H Hovelson; Javed Siddiqui; L Priya Kunju; Rodney L Dunn; Sarah Meyer; Petrea Hodge; Jack Groskopf; John T Wei; Arul M Chinnaiyan Journal: Eur Urol Date: 2015-05-16 Impact factor: 20.096
Authors: Amir H Lebastchi; Christopher M Russell; Yashar S Niknafs; Nicholas W Eyrich; Zoey Chopra; Rachel Botbyl; Rana Kabeer; Takahiro Osawa; Javed Siddiqui; Rabia Siddiqui; Matthew S Davenport; Rohit Mehra; Scott A Tomlins; Lakshimi P Kunju; Arul M Chinnaiyan; John T Wei; Jeffrey J Tosoian; Todd M Morgan Journal: Urology Date: 2020-08-08 Impact factor: 2.649
Authors: Simpa S Salami; Jeremy B Kaplan; Srinivas Nallandhighal; Mandeep Takhar; Jeffrey J Tosoian; Matthew Lee; Junhee Yoon; Daniel H Hovelson; Komal R Plouffe; Samuel D Kaffenberger; Edward M Schaeffer; R Jeffrey Karnes; Tamara L Lotan; Todd M Morgan; Arvin K George; Jeffrey S Montgomery; Matthew S Davenport; Sungyong You; Scott A Tomlins; Nicole E Curci; Hyung L Kim; Daniel E Spratt; Aaron M Udager; Ganesh S Palapattu Journal: JCO Precis Oncol Date: 2019-06-12
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen Journal: Lancet Date: 2014-08-06 Impact factor: 79.321
Authors: Jan P Radtke; Timur H Kuru; Silvan Boxler; Celine D Alt; Ionel V Popeneciu; Clemens Huettenbrink; Tilman Klein; Sarah Steinemann; Claudia Bergstraesser; Matthias Roethke; Wilfried Roth; Heinz-Peter Schlemmer; Markus Hohenfellner; Boris A Hadaschik Journal: J Urol Date: 2014-07-28 Impact factor: 7.450
Authors: Donna P Ankerst; Jing Xia; Ian M Thompson; Josef Hoefler; Lisa F Newcomb; James D Brooks; Peter R Carroll; William J Ellis; Martin E Gleave; Raymond S Lance; Peter S Nelson; Andrew A Wagner; John T Wei; Ruth Etzioni; Daniel W Lin Journal: Eur Urol Date: 2015-03-25 Impact factor: 20.096
Authors: Christina Fitzmaurice; Tomi F Akinyemiju; Faris Hasan Al Lami; Tahiya Alam; Reza Alizadeh-Navaei; Christine Allen; Ubai Alsharif; Nelson Alvis-Guzman; Erfan Amini; Benjamin O Anderson; Olatunde Aremu; Al Artaman; Solomon Weldegebreal Asgedom; Reza Assadi; Tesfay Mehari Atey; Leticia Avila-Burgos; Ashish Awasthi; Huda Omer Ba Saleem; Aleksandra Barac; James R Bennett; Isabela M Bensenor; Nickhill Bhakta; Hermann Brenner; Lucero Cahuana-Hurtado; Carlos A Castañeda-Orjuela; Ferrán Catalá-López; Jee-Young Jasmine Choi; Devasahayam Jesudas Christopher; Sheng-Chia Chung; Maria Paula Curado; Lalit Dandona; Rakhi Dandona; José das Neves; Subhojit Dey; Samath D Dharmaratne; David Teye Doku; Tim R Driscoll; Manisha Dubey; Hedyeh Ebrahimi; Dumessa Edessa; Ziad El-Khatib; Aman Yesuf Endries; Florian Fischer; Lisa M Force; Kyle J Foreman; Solomon Weldemariam Gebrehiwot; Sameer Vali Gopalani; Giuseppe Grosso; Rahul Gupta; Bishal Gyawali; Randah Ribhi Hamadeh; Samer Hamidi; James Harvey; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Behzad Heibati; Molla Kahssay Hiluf; Nobuyuki Horita; H Dean Hosgood; Olayinka S Ilesanmi; Kaire Innos; Farhad Islami; Mihajlo B Jakovljevic; Sarah Charlotte Johnson; Jost B Jonas; Amir Kasaeian; Tesfaye Dessale Kassa; Yousef Saleh Khader; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Mohammad Hossein Khosravi; Jagdish Khubchandani; Jacek A Kopec; G Anil Kumar; Michael Kutz; Deepesh Pravinkumar Lad; Alessandra Lafranconi; Qing Lan; Yirga Legesse; James Leigh; Shai Linn; Raimundas Lunevicius; Azeem Majeed; Reza Malekzadeh; Deborah Carvalho Malta; Lorenzo G Mantovani; Brian J McMahon; Toni Meier; Yohannes Adama Melaku; Mulugeta Melku; Peter Memiah; Walter Mendoza; Tuomo J Meretoja; Haftay Berhane Mezgebe; Ted R Miller; Shafiu Mohammed; Ali H Mokdad; Mahmood Moosazadeh; Paula Moraga; Seyyed Meysam Mousavi; Vinay Nangia; Cuong Tat Nguyen; Vuong Minh Nong; Felix Akpojene Ogbo; Andrew Toyin Olagunju; Mahesh Pa; Eun-Kee Park; Tejas Patel; David M Pereira; Farhad Pishgar; Maarten J Postma; Farshad Pourmalek; Mostafa Qorbani; Anwar Rafay; Salman Rawaf; David Laith Rawaf; Gholamreza Roshandel; Saeid Safiri; Hamideh Salimzadeh; Juan Ramon Sanabria; Milena M Santric Milicevic; Benn Sartorius; Maheswar Satpathy; Sadaf G Sepanlou; Katya Anne Shackelford; Masood Ali Shaikh; Mahdi Sharif-Alhoseini; Jun She; Min-Jeong Shin; Ivy Shiue; Mark G Shrime; Abiy Hiruye Sinke; Mekonnen Sisay; Amber Sligar; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Gizachew Assefa Tessema; Roman Topor-Madry; Tung Thanh Tran; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Elisabete Weiderpass; Hywel C Williams; Nigus Bililign Yimer; Naohiro Yonemoto; Mustafa Z Younis; Christopher J L Murray; Mohsen Naghavi Journal: JAMA Oncol Date: 2018-11-01 Impact factor: 31.777
Authors: Spyridon P Basourakos; Michael Tzeng; Patrick J Lewicki; Krishnan Patel; Bashir Al Hussein Al Awamlh; Siv Venkat; Jonathan E Shoag; Michael A Gorin; Christopher E Barbieri; Jim C Hu Journal: Front Oncol Date: 2021-05-28 Impact factor: 6.244
Authors: Jeffrey J Tosoian; Rodney L Dunn; Yashar S Niknafs; Anjan Saha; Randy A Vince; Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Javed Siddiqui; Jack Groskopf; Steven J Jacobsen; Scott A Tomlins; Lakshmi P Kunju; Todd M Morgan; Simpa S Salami; John T Wei; Arul M Chinnaiyan; Aruna V Sarma Journal: Eur Urol Open Sci Date: 2021-05-25